Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer

Back

23rd European Heart Disease and Heart Failure Congress

Paris, France

Ramzi EL FEGHALI

Omics & Nanotech, Sannois, FRANCE

Title: EPPB-AH Early Predictive Protein Biomarkers of Atherosclerosis and Hypertension

Biography

Biography: Ramzi EL FEGHALI

Abstract

 

Metabolic alterations and hypertension are the major risk factors of heart diseases development. Today a panel of 40 biomarkers jointly with clinical markers are used by the cardiologists for the diagnosis of coronary and heart diseases. Some predictive biomarkers are used for the prognostic of the coronary and heart diseases but those biomarkers present a lack of accuracy due to the complex molecular system of the blood, the vessels and the heart. For this reason, I have proposed a new study design coupled to a robust biostatistics analysis in order to select the most relevant predictive protein biomarkers of atherosclerosis and hypertension. Material and methods: The plasma of 30 patients with 6 different phenotypes (hypertension, hypercholesterolemia, diabetes mellitus, stroke/transient ischemic attack, coronary artery diseases  and healthy controls) included by the Utrecht Medical Centre University in Netherlands was profiled with the LC-MS/MS proteomics mass spectrometry technique after the depletion of the major proteins and the digestion of the proteome. A coupled robust comparative statistical analysis allowed to sort the identified proteins and to validate the most discriminative and predictive set of proteins that are under patenting. Conclusion: Twenty robust predictive biomarkers including renin, phospholipases, membrane matrix proteins and an uncharacterized protein were selected after this pilot study as a predictive set of biomarkers for the prognosis of atherosclerosis and hypertension. Acknowledgements: This work has been partly funded with a grant from the French Research Institute for Development of Marseille; the first experiments were realized by the CLinical Innovation Proteomic Platform of Dijon in France